In the latest session, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $9.03 down -0.88% from its previous closing price of $9.11. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 2540671 shares were traded.
Ratios:
For a deeper understanding of Ironwood Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.72. For the most recent quarter (mrq), Quick Ratio is recorded 0.84 and its Current Ratio is at 0.84.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on January 17, 2024, initiated with a Buy rating and assigned the stock a target price of $21.
On December 14, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $20.
On November 09, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $21.Jefferies initiated its Buy rating on November 09, 2023, with a $21 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 06 ’24 when Duane Jon R bought 6,920 shares for $8.70 per share. The transaction valued at 60,204 led to the insider holds 121,028 shares of the business.
Emany Sravan Kumar bought 10,684 shares of IRWD for $100,216 on Mar 04 ’24. The SVP, Chief Financial Officer now owns 301,733 shares after completing the transaction at $9.38 per share. On Feb 12 ’24, another insider, MCCOURT Thomas A, who serves as the Chief Executive Officer of the company, sold 177,164 shares for $15.24 each. As a result, the insider received 2,699,979 and left with 832,774 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 1.41B and an Enterprise Value of 2.04B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.19. Its current Enterprise Value per Revenue stands at 4.60 whereas that against EBITDA is -2.20.
Stock Price History:
Over the past 52 weeks, IRWD has reached a high of $15.70, while it has fallen to a 52-week low of $8.07. The 50-Day Moving Average of the stock is 12.45, while the 200-Day Moving Average is calculated to be 10.68.
Shares Statistics:
For the past three months, IRWD has traded an average of 4.78M shares per day and 7.12M over the past ten days. A total of 156.35M shares are outstanding, with a floating share count of 151.61M. Insiders hold about 3.14% of the company’s shares, while institutions hold 107.34% stake in the company. Shares short for IRWD as of Feb 29, 2024 were 15.51M with a Short Ratio of 3.25, compared to 14.46M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.91% and a Short% of Float of 16.14%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.16 for the current quarter, with a high estimate of $0.25 and a low estimate of $0.1, while EPS last year was $0.25. The consensus estimate for the next quarter is $0.18, with high estimates of $0.27 and low estimates of $0.12.
Analysts are recommending an EPS of between $0.87 and $0.51 for the fiscal current year, implying an average EPS of $0.68. EPS for the following year is $0.86, with 6 analysts recommending between $1.06 and $0.66.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $106.3M this quarter.It ranges from a high estimate of $111.7M to a low estimate of $102.1M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $100.41M, an estimated increase of 5.90% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $112.16M, an increase of 4.40% less than the figure of $5.90% in the same quarter last year. There is a high estimate of $114.5M for the next quarter, whereas the lowest estimate is $109.12M.
A total of 6 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $453.3M, while the lowest revenue estimate was $436.5M, resulting in an average revenue estimate of $448.27M. In the same quarter a year ago, actual revenue was $442.74M, up 1.30% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $490.56M in the next fiscal year. The high estimate is $526.6M and the low estimate is $461.1M. The average revenue growth estimate for next year is up 9.40% from the average revenue estimate for this year.
